Mapping paratope on antithrombotic antibody 6B4 to epitope on platelet glycoprotein Ibalpha via molecular dynamic simulations

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Fang, Xiang ^a   Fang, Ying ^a   Liu, Li ^a   Liu, Guangjian ^a   Wu, Jianhua ^a  

^a SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOTIC ANTIBODY 6B4; EPITOPE; GLYCOPROTEIN IB ALPHA; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ARTICLE; BINDING SITE; DRUG RECEPTOR BINDING; EPITOPE MAPPING; HYDROGEN BOND; MATHEMATICAL COMPUTING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR GENETICS; MOLECULAR MECHANICS; PARATOPE MAPPING; SEQUENCE HOMOLOGY; SURVIVAL RATE; THERMOSTABILITY;

BINDING SITES, ANTIBODY; EPITOPES; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR DYNAMICS SIMULATION; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; THROMBOSIS;

EID: 84864428245     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042263     Document Type: Article

References (38)

1. Savage B, Saldivar E, Ruggeri ZM, (1996) Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84: 289-297.
2. Ruggeri ZM, (2002) Platelets in atherothrombosis. Nat Med 8: 1227-1234.
3. Russell SD, Roth GJ, (1993) Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood 81: 1787-1791.
4. Sadler JE, (2005) New concepts in von Willebrand disease. Annu Rev Med 56: 173-191.
5. Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, de Groot PG, et al. (2002) Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 297: 1176-1179.
6. Sadler JE, (2002) Biomedicine. Contact-how platelets touch von Willebrand factor. Science 297: 1128-1129.
7. Dumas JJ, Kumar R, McDonagh T, Sullivan F, Stahl ML, et al. (2004) Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J Biol Chem 279: 23327-23334.
8. Chen Z, Lou J, Zhu C, Schulten K, (2008) Flow-induced structural transition in the beta-switch region of glycoprotein Ib. Biophys J 95: 1303-1313.
9. Lou J, Zhu C, (2008) Flow induces loop-to-beta-hairpin transition on the beta-switch of platelet glycoprotein Ib alpha. Proc Natl Acad Sci U S A 105: 13847-13852.
10. Yago T, Lou J, Wu T, Yang J, Miner JJ, et al. (2008) Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest 118: 3195-3207.
11. Shen Y, Romo GM, Dong JF, Schade A, McIntire LV, et al. (2000) Requirement of leucine-rich repeats of glycoprotein (GP) Ibalpha for shear-dependent and static binding of von Willebrand factor to the platelet membrane GP Ib-IX-V complex. Blood 95: 903-910.
12. Cauwenberghs N, Vanhoorelbeke K, Vauterin S, Westra DF, Romo G, et al. (2001) Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood 98: 652-660.
13. Zhao Y, Dong N, Shen F, Xie L, He Y, et al. (2007) Two novel monoclonal antibodies to VWFA3 inhibit VWF-collagen and VWF-platelet interactions. J Thromb Haemost 5: 1963-1970.
14. Cauwenberghs N, Meiring M, Vauterin S, van Wyk V, Lamprecht S, et al. (2000) Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol 20: 1347-1353.
15. Wu D, Meiring M, Kotze HF, Deckmyn H, Cauwenberghs N, (2002) Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol 22: 323-328.
16. Fontayne A, De Maeyer B, De Maeyer M, Yamashita M, Matsushita T, et al. (2007) Paratope and epitope mapping of the antithrombotic antibody 6B4 in complex with platelet glycoprotein Ibalpha. J Biol Chem 282: 23517-23524.
17. Adcock SA, McCammon JA, (2006) Molecular dynamics: Survey of methods for simulating the activity of proteins. Chemical Reviews 106: 1589-1615.
18. Long M, Sato M, Lim CT, Wu JH, Adachi T, et al. (2011) Advances in Experiments and Modeling in Micro- and Nano-Biomechanics: A Mini Review. Cellular and Molecular Bioengineering 4: 327-339.
19. Weaver DF, Sutherland JJ, O'Brien LA, Lillicrap D, (2004) Molecular modeling of the von Willebrand factor A2 domain and the effects of associated type 2A von Willebrand disease mutations. Journal of Molecular Modeling 10: 259-270.
20. Huang QS, Lou JZ, Wu JH, Zhu C, (2011) Conformational Transition of Glycoprotein Ib alpha Mutants in Flow Molecular Dynamics Simulation. Cellular and Molecular Bioengineering 4: 495-504.
21. Interlandi G, Thomas W, (2010) The catch bond mechanism between von Willebrand factor and platelet surface receptors investigated by molecular dynamics simulations. Proteins 78: 2506-2522.
22. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402.
23. Lefranc MP, Pommie C, Ruiz M, Giudicelli V, Foulquier E, et al. (2003) IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 27: 55-77.
24. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG, (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.
25. Sali A, Blundell TL, (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815.
26. Dai K, Zhu H, Ruan C, (2003) Generation and characterization of recombinant single chain Fv antibody that recognizes platelet glycoprotein Ibalpha. Thromb Res 109: 137-144.
27. Arcangeli C, Cantale C, Galeffi P, Rosato V, (2008) Structure and dynamics of the anti-AMCV scFv(F8): effects of selected mutations on the antigen combining site. J Struct Biol 164: 119-133.
28. Wilkinson IC, Hall CJ, Veverka V, Shi JY, Muskett FW, et al. (2009) High resolution NMR-based model for the structure of a scFv-IL-1beta complex: potential for NMR as a key tool in therapeutic antibody design and development. J Biol Chem 284: 31928-31935.
29. Mintseris J, Pierce B, Wiehe K, Anderson R, Chen R, et al. (2007) Integrating statistical pair potentials into protein complex prediction. Proteins 69: 511-520.
30. Pierce B, Weng Z, (2007) ZRANK: reranking protein docking predictions with an optimized energy function. Proteins 67: 1078-1086.
31. Pierce B, Weng Z, (2008) A combination of rescoring and refinement significantly improves protein docking performance. Proteins 72: 270-279.
32. Humphrey W, Dalke A, Schulten K, (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38, 27-38.
33. Mihel J, Sikic M, Tomic S, Jeren B, Vlahovicek K, (2008) PSAIA- protein structure and interaction analyzer. BMC Struct Biol 8: 21.
34. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802.
35. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, et al. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. Journal of Physical Chemistry B 102: 3586-3616.
36. Zhang B, Su ZC, Tay TE, Tan VB, (2010) Mechanism of CDK5 activation revealed by steered molecular dynamics simulations and energy calculations. Journal of Molecular Modeling 16: 1159-1168.
37. Isralewitz B, Baudry J, Gullingsrud J, Kosztin D, Schulten K, (2001) Steered molecular dynamics investigations of protein function. J Mol Graph Model 19: 13-25.
38. Dominguez C, Boelens R, Bonvin AM, (2003) HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc 125: 1731-1737.